<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625155</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001</org_study_id>
    <nct_id>NCT02625155</nct_id>
  </id_info>
  <brief_title>Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens</brief_title>
  <acronym>SPHERE</acronym>
  <official_title>Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSource Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InSource Diagnostics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of selective pharmacogenomic
      (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced
      by a reduction in Target Drug-related Adverse Events (TDRAE) over the period following
      enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who experience target drug-related adverse events (TDRAE) over the 90-day period following enrollment</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All TDRAE as quantified within each of the four classes of medications</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDRAE driving a change in the subject's drug regimen (dose change, discontinuation, substation, or addition of a new drug)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe TDRAE, defined as a TDRAE that meets the criteria for a Serious Adverse Event</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ineffective therapeutic response, determined by the Investigator</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supra-therapeutic response, as determined by the Investigator</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of subjects with changes in drug regimen</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare resource utilization, as measured by the number of outpatient clinic visits, emergency room/urgent care visits, and hospitalizations; tabulated over the 90-day period following enrollment</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14000</enrollment>
  <condition>Target Drug-related Adverse Events</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SOC Arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care UDT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective PGx Testing (Test Arm)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care UDT with selective PGx testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine diagnostic testing as SOC, drug regimen changes per SOC</intervention_name>
    <arm_group_label>Standard of Care (SOC Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results</intervention_name>
    <arm_group_label>Selective PGx Testing (Test Arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 12 years of age or older;

          2. Subject or legal representative is able and willing to provide informed consent;

          3. Subject has had a TDRAE including ineffective therapeutic response within the last 60
             days or is a new patient to the treating healthcare provider's practice;

          4. Subject is scheduled for or is planned to be scheduled for UDT, ordered as per the
             treating healthcare provider's local standard of care;

          5. Subject is currently receiving or the subject's treating healthcare provider is
             considering treatment with at least one target drug listed below and metabolized by
             one or more genes considered in this study: Amitriptyline, Imipramine, Diazepam,
             Alprazolam, Codeine, Hydrocodone, Oxycodone, Methadone, Meperidine, Fentanyl and
             Carisoprodol.

        Exclusion Criteria:

          1. Prior history of PGx testing for genes specific to any of the target drugs in the
             past;

          2. PGx testing is deemed mandatory in the opinion of the treating healthcare provider;

          3. History of liver or renal transplantation;

          4. Receiving chronic hemodialysis or peritoneal dialysis;

          5. Currently hospitalized or in a long-term care facility;

          6. Participation in another clinical trial that would, in the Investigator's opinion,
             interfere with the conduct of this study;

          7. Subject or subject's guardian or advocate is unable to provide an accurate history of
             the subject's medical history, medications, and symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Donald H. Deaton, Jr., DO</name>
      <address>
        <city>Tazewell</city>
        <state>Tennessee</state>
        <zip>37879</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald H. Deaton, DO</last_name>
      <phone>423-259-8076</phone>
    </contact>
    <investigator>
      <last_name>Donald H. Deaton, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Phimister EG, Feero WG, Guttmacher AE. Realizing genomic medicine. N Engl J Med. 2012 Feb 23;366(8):757-9. doi: 10.1056/NEJMe1200749.</citation>
    <PMID>22356329</PMID>
  </reference>
  <reference>
    <citation>Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, Chabert J, Dayer P, Hochstrasser D, Rossier MF. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009 Feb;9(1):34-41. doi: 10.1038/tpj.2008.7. Epub 2008 Jul 1.</citation>
    <PMID>18591960</PMID>
  </reference>
  <reference>
    <citation>Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. doi: 10.1002/cpt.147. Epub 2015 Jun 29. Review.</citation>
    <PMID>25974703</PMID>
  </reference>
  <reference>
    <citation>Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb;91(2):321-6. doi: 10.1038/clpt.2011.287. Epub 2011 Dec 28.</citation>
    <PMID>22205192</PMID>
  </reference>
  <reference>
    <citation>Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther. 1992 Aug;52(2):160-9.</citation>
    <PMID>1505151</PMID>
  </reference>
  <reference>
    <citation>Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist. 2006 Feb;11(2):126-35. Review.</citation>
    <PMID>16476833</PMID>
  </reference>
  <reference>
    <citation>Wijnen PA, Op den Buijsch RA, Drent M, Kuijpers PM, Neef C, Bast A, Bekers O, Koek GH. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007 Dec;26 Suppl 2:211-9. doi: 10.1111/j.1365-2036.2007.03490.x. Review. Erratum in: Aliment Pharmacol Ther. 2009 Feb 1;29(3):350. Kuipers, P M J C [corrected to Kuijpers, P M J C].</citation>
    <PMID>18081664</PMID>
  </reference>
  <reference>
    <citation>Linares OA, Fudin J, Daly AL, Boston RC. Individualized Hydrocodone Therapy Based on Phenotype, Pharmacogenetics, and Pharmacokinetic Dosing. Clin J Pain. 2015 Dec;31(12):1026-35. doi: 10.1097/AJP.0000000000000214.</citation>
    <PMID>25621429</PMID>
  </reference>
  <reference>
    <citation>Falzone E, Hoffmann C, Keita H. Postoperative analgesia in elderly patients. Drugs Aging. 2013 Feb;30(2):81-90. doi: 10.1007/s40266-012-0047-7. Review.</citation>
    <PMID>23288604</PMID>
  </reference>
  <reference>
    <citation>Balhara YP, Jain R. A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance. J Pharmacol Pharmacother. 2012 Jan;3(1):15-9. doi: 10.4103/0976-500X.92496.</citation>
    <PMID>22368411</PMID>
  </reference>
  <reference>
    <citation>Christo PJ, Manchikanti L, Ruan X, Bottros M, Hansen H, Solanki DR, Jordan AE, Colson J. Urine drug testing in chronic pain. Pain Physician. 2011 Mar-Apr;14(2):123-43. Review.</citation>
    <PMID>21412368</PMID>
  </reference>
  <reference>
    <citation>Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, Zobel A, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ. Adverse reactions to antidepressants. Br J Psychiatry. 2009 Sep;195(3):202-10. doi: 10.1192/bjp.bp.108.061960. Erratum in: Br J Psychiatry. 2010 May;196(5):417.</citation>
    <PMID>19721108</PMID>
  </reference>
  <reference>
    <citation>Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association. BMC Clin Pharmacol. 2011 Oct 25;11:16. doi: 10.1186/1472-6904-11-16.</citation>
    <PMID>22026961</PMID>
  </reference>
  <reference>
    <citation>Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep. 2015 Jul;17(7):50. doi: 10.1007/s11920-015-0594-9. Review.</citation>
    <PMID>25980509</PMID>
  </reference>
  <reference>
    <citation>Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007 Apr;58(4):489-95.</citation>
    <PMID>17412850</PMID>
  </reference>
  <reference>
    <citation>Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, Benser M, Edmondson AC, Bates DW. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000 Aug 1;109(2):87-94.</citation>
    <PMID>10967148</PMID>
  </reference>
  <reference>
    <citation>Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008 Jan;83(1):66-76. doi: 10.4065/83.1.66. Review. Erratum in: Mayo Clin Proc. 2008 Jul;83(7):851.</citation>
    <PMID>18174009</PMID>
  </reference>
  <reference>
    <citation>Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012 Oct;92(4):467-75. doi: 10.1038/clpt.2012.120. Epub 2012 Sep 5.</citation>
    <PMID>22948889</PMID>
  </reference>
  <reference>
    <citation>Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010 Jul 22;363(4):301-4. doi: 10.1056/NEJMp1006304. Epub 2010 Jun 15. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092.</citation>
    <PMID>20551152</PMID>
  </reference>
  <reference>
    <citation>Yiannakopoulou E. Pharmacogenomics and Opioid Analgesics: Clinical Implications. Int J Genomics. 2015;2015:368979. doi: 10.1155/2015/368979. Epub 2015 May 14. Review.</citation>
    <PMID>26075211</PMID>
  </reference>
  <reference>
    <citation>Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012 Mar;91(3):450-8. doi: 10.1038/clpt.2011.306. Epub 2012 Jan 25.</citation>
    <PMID>22278335</PMID>
  </reference>
  <reference>
    <citation>Deverka PA. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics. 2009;12(3):149-57. doi: 10.1159/000189627. Epub 2009 Feb 10.</citation>
    <PMID>19204417</PMID>
  </reference>
  <reference>
    <citation>Local Coverage Determination (LCD): CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing (L35472). 2015. (Accessed 8/10/2015, at https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=35472&amp;ContrId=357.)</citation>
  </reference>
  <reference>
    <citation>Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: tools, techniques, and utility. Pain Physician. 2008 Mar;11(2 Suppl):S155-80. Review.</citation>
    <PMID>18443638</PMID>
  </reference>
  <reference>
    <citation>Konstantinova SV, Normann PT, Arnestad M, Karinen R, Christophersen AS, Mørland J. Morphine to codeine concentration ratio in blood and urine as a marker of illicit heroin use in forensic autopsy samples. Forensic Sci Int. 2012 Apr 10;217(1-3):216-21. doi: 10.1016/j.forsciint.2011.11.007. Epub 2011 Dec 2.</citation>
    <PMID>22137531</PMID>
  </reference>
  <reference>
    <citation>Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010 Mar 1;81(5):635-40.</citation>
    <PMID>20187600</PMID>
  </reference>
  <reference>
    <citation>Disability Evaluation Under Social Security. (Accessed 3/5/2014, 2014, at http://www.ssa.gov/disability/professionals/bluebook/general-info.htm.)</citation>
  </reference>
  <reference>
    <citation>Inter-agency guideline for opioid dosing for chronic non-cancer pain.2010.</citation>
  </reference>
  <reference>
    <citation>National Bioeconomy Blueprint. The White House; 2012:48.</citation>
  </reference>
  <reference>
    <citation>World Guide for Drug Use and Pharmacogenomics. Corunna, Spain: EuroEspes Publishing; 2012.</citation>
  </reference>
  <reference>
    <citation>Model policy on the use of opioid analgesics in the treatment of chronic pain. Federation of State Medical Boards; 2013.</citation>
  </reference>
  <reference>
    <citation>ACOEM. Guidelines for the Chronic Use of Opioids. 2 ed: American College of Occupational and Environmental Medicine.</citation>
  </reference>
  <reference>
    <citation>Michna E, Jamison RN, Pham LD, Ross EL, Janfaza D, Nedeljkovic SS, Narang S, Palombi D, Wasan AD. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain. 2007 Feb;23(2):173-9.</citation>
    <PMID>17237667</PMID>
  </reference>
  <reference>
    <citation>Wiedemer NL, Harden PS, Arndt IO, Gallagher RM. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med. 2007 Oct-Nov;8(7):573-84.</citation>
    <PMID>17883742</PMID>
  </reference>
  <reference>
    <citation>Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW. Adverse drug events in ambulatory care. N Engl J Med. 2003 Apr 17;348(16):1556-64.</citation>
    <PMID>12700376</PMID>
  </reference>
  <reference>
    <citation>Manchikanti L, Manchikanti KN, Pampati V, Cash KA. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain. Pain Physician. 2009 Jan-Feb;12(1):259-67.</citation>
    <PMID>19165308</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>December 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacogenomics</keyword>
  <keyword>Urine Drug Testing</keyword>
  <keyword>antidepressants</keyword>
  <keyword>benzodiazepines</keyword>
  <keyword>opioids</keyword>
  <keyword>muscle relaxants</keyword>
  <keyword>non-steroidal anti-inflammatory agents</keyword>
  <keyword>TDRAE</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

